161 related articles for article (PubMed ID: 22187356)
1. Presenting Germany's drug pricing rule as a cost-per-QALY rule.
Gandjour A
Health Care Manag Sci; 2012 Jun; 15(2):103-7. PubMed ID: 22187356
[TBL] [Abstract][Full Text] [Related]
2. Drug pricing and control of health expenditures: a comparison between a proportional decision rule and a cost-per-QALY rule.
Gandjour A
Int J Health Plann Manage; 2015; 30(4):395-402. PubMed ID: 24789123
[TBL] [Abstract][Full Text] [Related]
3. Germany's decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules.
Gandjour A
Appl Health Econ Health Policy; 2011 Mar; 9(2):65-71. PubMed ID: 21332250
[TBL] [Abstract][Full Text] [Related]
4. Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG.
Gandjour A
BMC Health Serv Res; 2020 Apr; 20(1):343. PubMed ID: 32321496
[TBL] [Abstract][Full Text] [Related]
5. A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG).
Gandjour A
Health Serv Manage Res; 2013 Nov; 26(4):103-9. PubMed ID: 25595007
[TBL] [Abstract][Full Text] [Related]
6. [Should IQWiG revise its methods of cost-effectiveness analysis in order to comply with more widely accepted health economical evaluation standards?].
Lübbe W
Dtsch Med Wochenschr; 2010 Mar; 135(12):582-5. PubMed ID: 20234995
[TBL] [Abstract][Full Text] [Related]
7. Rebates-The Little-Known Factor Behind Increasing Drug List Prices.
Rubin R
JAMA; 2020 Mar; 323(9):812-813. PubMed ID: 32125400
[No Abstract] [Full Text] [Related]
8. Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor.
Gandjour A; Gafni A; Schlander M
Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):123-9. PubMed ID: 24354766
[TBL] [Abstract][Full Text] [Related]
9. [Medication prices in Germany--how are they determined?].
Bruhn C
Dtsch Med Wochenschr; 2010 Oct; 135(39):p34. PubMed ID: 20922657
[No Abstract] [Full Text] [Related]
10. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
11. A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency.
Gandjour A
BMC Health Serv Res; 2020 Mar; 20(1):240. PubMed ID: 32293433
[TBL] [Abstract][Full Text] [Related]
12. Drug-Pricing Debate Redux - Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?
Neumann PJ; Cohen JT; Ollendorf DA
N Engl J Med; 2021 Nov; 385(21):1923-1924. PubMed ID: 34767318
[No Abstract] [Full Text] [Related]
13. [Cost-effectiveness evaluation of drugs: multidisciplinary collaboration and transparency are key].
Mueller EA; Kirch W
Med Klin (Munich); 2008 Oct; 103(10):712-6. PubMed ID: 18936896
[TBL] [Abstract][Full Text] [Related]
14. Cost Recommendation under Uncertainty in IQWiG's Efficiency Frontier Framework.
Corro Ramos I; Lhachimi SK; Gerber-Grote A; Al MJ
Med Decis Making; 2017 Feb; 37(2):162-172. PubMed ID: 27005521
[TBL] [Abstract][Full Text] [Related]
15. Lower Prices and Greater Patient Access - Lessons from Germany's Drug-Purchasing Structure.
Robinson JC
N Engl J Med; 2020 Jun; 382(23):2177-2179. PubMed ID: 32492300
[No Abstract] [Full Text] [Related]
16. States on the Front Line: Addressing America's Drug Pricing Problem.
Riley T; Lanford S
J Leg Med; 2019; 39(2):81-93. PubMed ID: 31503529
[No Abstract] [Full Text] [Related]
17. [Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].
Krauth C; John J; Aidelsburger P; Brüggenjürgen B; Hansmeier T; Hessel F; Kohlmann T; Moock J; Rothgang H; Schweikert B; Seitz R; Wasem J;
Gesundheitswesen; 2008 Jun; 70(6):e1-16. PubMed ID: 18661452
[TBL] [Abstract][Full Text] [Related]
18. Targeting Unconscionable Prescription-Drug Prices - Maryland's Anti-Price-Gouging Law.
Greene JA; Padula WV
N Engl J Med; 2017 Jul; 377(2):101-103. PubMed ID: 28591520
[No Abstract] [Full Text] [Related]
19. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
Schlette S; Hess R
Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
[TBL] [Abstract][Full Text] [Related]
20. The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs.
Gudiksen KL; King JS
J Leg Med; 2019; 39(2):95-120. PubMed ID: 31503534
[No Abstract] [Full Text] [Related]
[Next] [New Search]
